Search
Lexeo Therapeutics' CEO Nolan Townsend highlights recent FA cardiomyopathy data and the path ahead in that indication. Plus, the latest on PKP2 ACM, and more
He describes the clinical data in FA cardiomyopathy that was announced this month, and explains how the company is preparing to begin a...
4 hours ago
Metsera's CEO Whit Bernard on the obesity space, including GLP-1s, amylin analogs, and how the company is also developing both as oral peptides
He describes how Metsera, which had its IPO two months ago, is aiming to develop a differentiated GLP-1 vs currently marketed products by...
6 hours ago
On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73
He describes the market potential of the company's HIF-2⍺, a target that has already been de-risked by a large pharma, why he believes...
7 days ago
Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies
Founder and CEO Nicole Paulk describes the process, which allows the public to invest as little as $100, and why she views the investors...
Apr 16
Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)
CEO Rick Winningham describes the science behind ampreloxetine, and the rationale for developing it for patients with multiple system...
Apr 15
Marea Therapeutics today announced acceptance of a late-breaker at #EASCongress2025 for its ANGPTL4 inhibitor - believed to be the first ever clinical data presented for this lipid lowering target
CEO Josh Lehrer and CSO Ethan Weiss describe the biology of the target and highlight the topline data, which was first announced at...
Apr 15
After switching to a new GalNAc-LNP delivery vehicle a year ago, Verve Therapeutics today announced the initial safety and efficacy data from its VERVE-102 PCSK9 base editor
Co-Founder & CEO Sek Kathiresan walks us through the data, which so far has showed a clean safety profile and an impressive ability to...
Apr 14
Jones Healthcare & Technology Innovation Conference: Pharvaris is developing oral bradykinin B2 receptor inhibitors for HEA - with a first pivotal scheduled to read in less than a year
CFO David Nassif describes the unmet need that still exists today in HAE, and updates us on programs in both the acute and prophylactic...
Apr 9
Jones Healthcare & Technology Innovation Conference: Biotech veteran David Hung on his company Nuvation Bio, which has an FDA decision for its ROS1 scheduled for June
He describes where this fits into the ROS1 space, and the data that has been derived for the filing. Plus, mIDH1, drug-drug-conjugates,...
Apr 9
Jones Healthcare & Technology Innovation Conference: Wave CEO Paul Bolno discusses recent DMD data and regulatory feedback, and shares updates on alpha-1 antitrypsin, obesity, and Huntington's
He describes the 48 week data for the exon 53 DMD program, and discusses the company's plan to seek accelerated approval. Plus, guidance...
Apr 9
Jones Healthcare & Technology Innovation Conference: The CIO of XOMA Royalty describes the inner workings of the royalty business, and also how to help with biotech's negative enterprise problem
Brad Sitko describes how XOMA is able to do smaller deals than other larger investors in this space, and he gives examples of investments...
Apr 9
Jones Healthcare & Technology Innovation Conference: Trevi Therapeutics CEO Jennifer Good describes recent positive data in refractory chronic cough and previews upcoming IPF data
She describes how the mechanism of Haduvio differs from other programs in chronic cough, and covers the recent phase 2a RIVER data....
Apr 9
Anglo Nordic Life Science Conference: Denmark based Synklino is developing a fusion protein that targets US28 for CMV infections from transplants
Co-Founder and CEO Thomas Kledal describes the science behind this platform and program. Plus, how having access to donated kidneys is...
Apr 3
On the heels of raising a $65M series B, the CEO of Flagship's Ampersand Biomedicines describes the company's precision medicine platform, and gives updates on partnering and R&D progress
CEO Jason Gardner describes Ampersand's platform that is designed to make medicines act at the site of disease. He also shares updates on...
Apr 3
BioTrinity 2025: With a novel E3 ubiquitin ligase (TRIM21) for protein degradation, Cambridge, UK based TRIMTECH Therapeutics recently raised a $31 million seed round
CEO Nicki Thompson describes why she believes the company is differentied in the field, and how TRIMTECH's construct is designed to...
Apr 2
After a $93M series B, Character Bio's CEO Cheng Zhang describes how the company has built a proprietary database to reclassify AMD patients into genetic subgroups to optimize trial patient selection
He describes why a 'one-size-fits-all' approach has caused numerous ophthalmology trials to fail in the past, and why Character believes...
Apr 1
Candel Therapeutics CEO Paul Peter Tak and IDEA Pharma CEO Mike Rea on why they believe a different mindset and good communication are keys to succeeding with new innovations in biotech
They discuss the difference between how biotech companies operate from large pharmas, including how history shows some new biotech...
Apr 1
BioTrinity 2025: AlveoGene Executive Chair David Hipkiss describes the company's unique inhaled gene therapy platform that fuses a Sendai virus and Lentivirus, and can be redosed
He describes the science behind the platform, which is already being used by Boehringer Ingelheim for cystic fibrosis. AlveoGene has...
Apr 1
Miami based Galatea Bio raised $25M today to expand its 'Galatea Global Biobank', an initiative to sequence 10 million participants worldwide, with a focus on individuals of non-European ancestry
Founder and CEO Carlos Bustamante tells BiotechTV's AI Correspondent, Ryan Flinn, about the biobank and why it is important to better...
Mar 27
State of Possible: Winner of the MassBioDrive Startup of the Year Award last year, the Co-Founder and CEO of Eascra Biotech describes developing nanoparticles as a delivery vehicle for therapies
Mari Anne Snow describes the advantages she sees nanoparticles having over current modalities like viral vectors, LNPs, and others.
Mar 26
.png){kind=logo}
